Wheeler Bio Secures $35M in Series A Funding to Revolutionize Biopharma Development

Wheeler Bio, Inc. is proud to announce a significant milestone in our journey toward transforming biopharmaceutical development with our recent funding announcement, having raised $35,000,000. This substantial investment will accelerate our mission as a pioneering Contract Development and Manufacturing Organization (CDMO) that specializes in smoothing the transition from discovery to development in the biopharma industry. Our innovative partnering model is designed to eliminate bottlenecks typically encountered during the early stages of drug discovery, and this funding enables us to further empower our collaborators in bringing novel antibody and antibody-like therapeutics to market with remarkable precision, speed, and cost-effectiveness without compromising on quality. With our cutting-edge Portable CMC® platform at the heart of our operations, we are uniquely equipped to offer comprehensive services including mammalian cell line and process development, GLP Tox material supply, and CGMP clinical supply. The infusion of capital will be strategically directed toward enhancing our proprietary technologies, expanding our state-of-the-art facilities, and solidifying our role as a trusted partner in bridging the critical gap between discovery and clinical trials. Additionally, we plan to invest in advanced research initiatives and talent recruitment that will bolster our capabilities, ultimately reducing lifecycle challenges and fostering enduring collaborations across the biopharma landscape. This is an exciting time for Wheeler Bio, Inc. and our partners, as we continue to address industry needs with innovation and expertise, striving to bring life-changing therapies to patients faster and more efficiently than ever before.